Drugs of interest to pathologists
Drugs related to surgical pathology

Topic Completed: 1 January 2012

Minor changes: 22 August 2019

Copyright: (c) 2002-2019, PathologyOutlines.com, Inc.

PubMed Search: Panitumumab [title] review

Him G. Kwee, M.D.
Page views in 2019: 48
Page views in 2020 to date: 17
Cite this page: Kwee HG. Panitumumab. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/drugspanitumumab.html. Accessed August 3rd, 2020.
Definition / general
  • Fully human monoclonal antibody directed against EGFR (epidermal growth factor receptor)
Trade name
  • Vectibix®
Clinical information
Approved by US Food and Drug Administration:
Molecular pathology - theory
  • Like cetuximab (Erbitux), panitumumab inhibits the extracellular domain of EGFR but cetuximab is a chimeric (human / mouse) antibody and panitumumab is a full human monoclonal antibody
  • With cetuximab, there is a high incidence of IgE mediated anaphylactic reactions; these reactions have not been seen with panitumumab (BMC Clin Pharmacol 2011;11:17)
  • Cetuximab is an IgG1 antibody but panitumumab is an IgG2 antibody; IgG1 can activate the complement pathway and mediate antibody dependent cellular cytotoxicity (Wikipedia: Panitumumab [Accessed 14 December 2018])
  • KRAS mutational analysis must be performed before treatment with cetuximab or panitumumab; these drugs cannot be used if there is a KRAS mutation in codons 12 or 13 (Arch Pathol Lab Med 2012;136:26)
Back to top